Skip to content

Recent advances in theranostic nanomaterials for overcoming traumatic brain injury

Document Type
Publications · Review Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Journal
JOURNAL OF NANOBIOTECHNOLOGY23(1) · #692 · 2025
Citation
Web of Science 13Scopus 15
FWCI (Scopus)
0.88
JCR IF
JCR 2024 12.6
ISSN
1477-3155

Authors

  1. Hwang, Nam CheolFirst authorKyung Hee Univ, Grad Sch, Dept Biomed Sci, Seoul 02447, South Korea
  2. Lim, Dong MinPusan Natl Univ, Interdisciplinary Program Genom Data Sci, Yangsan 50612, South Korea
  3. Goh, Tae SikPusan Natl Univ Hosp, Biomed Res Inst, Busan 49241, South Korea
  4. 강정모Pusan Natl Univ Hosp, Biomed Res Inst, Busan 49241, South Korea
  5. Kim, JaehoonKyung Hee Univ, Coll Med, Seoul 02447, South Korea
  6. Kim, ShinCorresponding authorKeimyung Univ, Sch Med, Dept Immunol, Daegu 42601, South Korea
  7. Kim, Yun HakCorresponding authorPusan Natl Univ, Sch Med, Dept Anat, Yangsan 50612, South Korea
  8. Kim, DokyoungCorresponding authorKyung Hee Univ, Grad Sch, Dept Biomed Sci, Seoul 02447, South Korea

Abstract

Traumatic brain injury (TBI) is a major global health challenge characterized by complex secondary injury mechanisms involving oxidative stress, inflammation, and blood-brain barrier (BBB) disruption. Traditional biosensing and therapy strategies often face limitations due to ineffective biomarker detection and poor drug targeting at the injury site. Recently, theranostic nanomaterials have emerged as a promising solution, integrating diagnostic and therapeutic functionalities within a single nanoscale platform. This review explores the latest advances in nanotherapeutics and nanosensors for TBI management. The first section summarizes various nanotherapeutic approaches, including PEGylated-polystyrene nanoparticles, porous silicon nanoparticles, carbon dot nanoparticles, dendrimer nanoparticles, lipid nanoparticles (LNPs), and siRNA-based nanoparticles, all of which have demonstrated enhanced neuroprotection and targeted drug delivery in TBIs. Notably, LNPs exhibit further optimized biocompatibility and therapeutic efficacy, while carbon dot nanoparticles function as nanozymes to combat oxidative stress, thereby mitigating neuronal damage. The second section focuses on nanosensors for TBIs, including peptide-based nanosensors, ECM-targeted nanosensors, and biomarker-responsive platforms capable of real-time diagnosis and monitoring of TBI progression. Additionally, the use of polymeric and fibrinogen-based nanosensors is discussed as advanced strategies to improve precision detection and therapeutic control. This review provides a comprehensive overview of theranostic nanomaterials for TBIs, highlighting their transformative potential in diagnosis and targeted treatment, while addressing key translational challenges to clinical application.

Keywords

BrainNanotherapeuticsDrug deliveryTranslational researchBiomedical engineeringCONTROLLED CORTICAL IMPACTCLINICAL-TRIALTHERAPEUTIC TARGETOXIDATIVE STRESSOLDER-ADULTSMOUSE MODELRAT MODELCALPAINBARRIERPROGESTERONE

Identifiers

Scopus EID
2-s2.0-105020259194
WoS UID
001603121500001